BioCentury | Jul 2, 2012
Finance

2Q Stock Wrap-Up: Magic in mid-caps

...drug Xiapex collagenase clostridium histolyticum that finds no additional benefit because the dossier was incomplete Bioxyne Ltd....
BioCentury | Jul 2, 2012
Clinical News

HI-1640V: Preliminary Phase IIb data

...exacerbations across both treatment groups and explain the difference between HI-H002 and HI-H005. In April, Bioxyne...
...other indications. In March, Probiomics Ltd. completed its acquisition of Hunter Immunology Ltd. to form Bioxyne...
...April 2). At March 31, the merged entity had A$2.5 million ($2.6 million) in cash. Bioxyne Ltd....
BioCentury | Jun 29, 2012
Clinical News

Bioxyne reports Phase IIb COPD data for HI-164OV

...is an enteric-coated tablet containing 45 mg of formalin inactivated Haemophilus influenzae . On Thursday, Bioxyne...
BioCentury | Apr 2, 2012
Company News

Hunter Immunology, Probiomics deal

...Exchange (ASX) and implemented a 1-for-20 share consolidation. The surviving entity, which will be renamed Bioxyne Ltd....
...the ASX on April 4 (see BioCentury, Jan. 2). Hunter Immunology Ltd. , Sydney, Australia Probiomics...
BioCentury | Jan 2, 2012
Company News

Hunter Immunology, Probiomics deal

...Hunter's board recommended that shareholders accept an October merger offer from probiotics company Probiomics. The stock...
...June 30, 2011. The deal, which is subject to Probiomics shareholder approval as well as Probiomics...
...the merger, the surviving entity will be renamed Bioxyne Ltd. Hunter Immunology Ltd. , Sydney, Australia Probiomics...
BioCentury | Jul 18, 2011
Company News

Proquifin S.A. de C.V., Vanda sales and marketing update

Vanda granted Proquifin's Probiomed S.A. de C.V. pharmaceutical operating unit exclusive rights in Mexico to commercialize schizophrenia drug Fanapt iloperidone. Probiomed, which is responsible for gaining regulatory approval in Mexico, plans to submit a marketing...
BioCentury | May 16, 2005
Finance

Taking the ADR route

...Denmark BNY 12/23/02 Chemgenex OTC CXSFY Australia BNY 12/6/02 Roche OTC RHHBY Switzerland BNY 12/5/02 VRI Biomedical...
Items per page:
1 - 7 of 7
BioCentury | Jul 2, 2012
Finance

2Q Stock Wrap-Up: Magic in mid-caps

...drug Xiapex collagenase clostridium histolyticum that finds no additional benefit because the dossier was incomplete Bioxyne Ltd....
BioCentury | Jul 2, 2012
Clinical News

HI-1640V: Preliminary Phase IIb data

...exacerbations across both treatment groups and explain the difference between HI-H002 and HI-H005. In April, Bioxyne...
...other indications. In March, Probiomics Ltd. completed its acquisition of Hunter Immunology Ltd. to form Bioxyne...
...April 2). At March 31, the merged entity had A$2.5 million ($2.6 million) in cash. Bioxyne Ltd....
BioCentury | Jun 29, 2012
Clinical News

Bioxyne reports Phase IIb COPD data for HI-164OV

...is an enteric-coated tablet containing 45 mg of formalin inactivated Haemophilus influenzae . On Thursday, Bioxyne...
BioCentury | Apr 2, 2012
Company News

Hunter Immunology, Probiomics deal

...Exchange (ASX) and implemented a 1-for-20 share consolidation. The surviving entity, which will be renamed Bioxyne Ltd....
...the ASX on April 4 (see BioCentury, Jan. 2). Hunter Immunology Ltd. , Sydney, Australia Probiomics...
BioCentury | Jan 2, 2012
Company News

Hunter Immunology, Probiomics deal

...Hunter's board recommended that shareholders accept an October merger offer from probiotics company Probiomics. The stock...
...June 30, 2011. The deal, which is subject to Probiomics shareholder approval as well as Probiomics...
...the merger, the surviving entity will be renamed Bioxyne Ltd. Hunter Immunology Ltd. , Sydney, Australia Probiomics...
BioCentury | Jul 18, 2011
Company News

Proquifin S.A. de C.V., Vanda sales and marketing update

Vanda granted Proquifin's Probiomed S.A. de C.V. pharmaceutical operating unit exclusive rights in Mexico to commercialize schizophrenia drug Fanapt iloperidone. Probiomed, which is responsible for gaining regulatory approval in Mexico, plans to submit a marketing...
BioCentury | May 16, 2005
Finance

Taking the ADR route

...Denmark BNY 12/23/02 Chemgenex OTC CXSFY Australia BNY 12/6/02 Roche OTC RHHBY Switzerland BNY 12/5/02 VRI Biomedical...
Items per page:
1 - 7 of 7